Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Armand, Philippe  [Clear All Filters]
Journal Article
Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, et al. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. Biol Blood Marrow Transplant. 2019.
Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Bin Chen Y-, Kaminski MS, H Holland K, Winter JN, Mason JR, et al. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. J Clin Oncol. 2013.
Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, et al. Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, et al. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Perales M-A, Sauter C, Armand P. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biol Blood Marrow Transplant. 2015.
Murase K, Kim HT, Bascug ORGregory, Kawano Y, Ryan J, Matsuoka K-I, Davids MS, Koreth J, Ho VT, Cutler C, et al. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Bin Chen Y-, McSweeney P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Bin Chen Y-, Cutler CS, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016.
Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, Lacasce AS, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122-126.
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, et al. Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol. 2020.
Zinzani PLuigi, Chen R, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, et al. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma. 2020:1-5.
Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, et al. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma. Haematologica. 2013.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4(5):858-867.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. Blood. 2014.